EICHORCondition: Total Knee Arthroplasty · Sponsor: Rush University Medical Center
The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Stanford University | Redwood City, California, United States | — |
| University of California, San Francisco | San Francisco, California, United States | — |
| Rush University medical Center | Chicago, Illinois, United States | — |
| Mass General Brigham | Somerville, Massachusetts, United States | — |
| Mayo Clinic Institutional Review | Rochester, Minnesota, United States | — |
| Washington University | St Louis, Missouri, United States | — |
| NYU Langone Health | New York, New York, United States | — |
| Columbia University Irving Medical Center | New York, New York, United States | — |
| University of Pennsylvania Perelman School of Medicine | Philadelphia, Pennsylvania, United States | — |
| Jefferson Philadelphia University and Thomas Jefferson University | Philadelphia, Pennsylvania, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05018091